HealthCare Global Enterprises Limited (HCG) Earnings Call Transcript & Summary
February 27, 2025
Earnings Call Speaker Segments
Operator
operatorGood day, everyone, and welcome to HealthCare Global Enterprises Limited's Q3 and 9 Months FY '25 Earnings Conference Call. This call may include forward-looking statements regarding the company, which rest on the beliefs, opinions and expectations of the company as of the date of this call. Such statements do not guarantee the company's future performance and may involve risks and uncertainties that are hard to predict. <<operator_script>> Please be aware that this conference is being recorded. I now hand the conference over to Dr. B.S. Ajaikumar, Promoter of HealthCare Global Enterprises Limited. Thank you, and over to you, sir.
B. Kumar
executiveThanks so much, and good morning, everybody. As all of us are aware, HCG has been featured in news coverage lately — and the bulk of that coverage became public over the past week. I'd simply like to restate that, as we know, a change has occurred in which CVC sold its stake — the majority of it — to KKR. At this point, we welcome KKR as our partner. Since most of the news is already out publicly, and we have nothing much — nothing further to add on that, I won't go into this matter any further. And moving on — as we know, with KKR coming in, we are certainly looking at a long-term horizon for how HCG can grow. As all of us are well aware, oncology is expanding quickly in India, and particularly for a group like ours, which is dedicated to oncology with comprehensive cancer centers and is setting up spokes and infusion centers, that represents a good strategic growth opportunity for us as we move forward. With close to 25 centers already in place, the opportunity for us to grow is significant when it comes to delivering the right care to the patient at the right place and at the right time.
B. Kumar
executiveAs I've said before, cancer is a disease that calls for highly personalized, focused therapy. And on that point, I've always held that getting the treatment right the first time is essential. That's why precision oncology has gained such traction today. What we focus on is how to treat the patient at the right moment, on the first attempt, so they get the greatest benefit. And with that in mind, we want to reduce how often cancer comes back as we go forward. A huge amount of information is emerging in oncology care these days. Previously, when we had randomized trials, we would treat patients and say, for instance, 50% will respond or 50% will not respond, and 50% used to receive treatment they didn't need. But now, with what we can deliver through precision oncology in the era of genomics, the era of proteomics, all of this has only widened the role of comprehensive cancer centers in making sure the right treatment is given to the patient. And this has genuinely stood in the way of how HCG can deliver precision medicine. Because of that, HCG has built research and academics into its operations. These days, I believe no oncology center can truly do what's right for the patient unless it is engaged in research, data collection and academics.
B. Kumar
executiveHCG is right at the leading edge of this. Technology and artificial intelligence — how we approach computational work, something we've partnered on with Accenture — will play a big part in bringing precision medicine to our own patients here in India. There's another angle I'd like to raise with you: most of you know well that Indian genomics differs from that of Caucasians. As a result, many of those past trials, and the treatments given, may have been tied to Caucasian populations. On this front too, we've moved to the leading edge when it comes to analyzing genomics. More than 2,000 patients have been studied by us, pinpointing where the problems lie and how the right treatment can be delivered the first time around. So here, I'd like to say that with new partners joining, adopting a long-term horizon, we will certainly focus — beyond the areas that exist for mergers, acquisitions, and growth of the HCG centers themselves, which you'll be hearing about in the future — we will also place substantial focus on academics as well as research and precision medicine. So my own view is that HCG holds a great opportunity for this type of growth, and we'll keep pursuing it with more than 400 oncologists alongside us, plus a sizable research division within our organization.
B. Kumar
executiveThat's all I have to say, so I'll turn things over to Mr. Raj Gore, who will go into more detail on operations and other matters. Many thanks.
Meghraj Gore
executiveThank you, Dr. Ajai. I'd like to give a very warm welcome to everyone joining us on the Q3 FY '25 earnings conference call. We're proud to report that we've once again managed to post our highest quarterly revenue ever, at INR 559 crores in the last quarter, which reflects strong growth of 19% on a Y-o-Y basis. Even though this was a seasonally weak quarter because of festivities and holidays, we were able to grow our volumes across modalities, which points to a gain in our market share across regions. Adjusted EBITDA margin came in at 16.5% for Q3 FY '25, with adjusted EBITDA of INR 92.3 crores, up 15% on a year-on-year basis, along with a PAT growth of 23%. The oncology business, after the MG Hospital Vizag acquisition, grew by 24%. Our emerging centers kept performing well in Q3, with 25% year-on-year growth. The Kolkata center grew by 40%, and the South Mumbai center grew by 28%. The South Mumbai center delivered a strong performance despite challenges in international business stemming from geopolitical issues, which we expect to recover by the upcoming quarter and which will be key for the center's turnaround. During the quarter, we consolidated operations of MG Hospital in Vizag. This acquisition has been instrumental in enhancing our footprint in the region, allowing us to further expand our services and strengthen our presence in one of the key markets for cancer care.
Meghraj Gore
executiveWe feel sure these centers will grow strongly, with performance getting better thanks to building a strong brand, having quality clinical talent, and running more awareness programs focused on cancer care and early diagnosis. At HCG, our belief is that world-class cancer care ought to be patient-centric, accessible and sustainable. Because of our asset-light model, we can expand efficiently, making sure that cutting-edge treatment reaches more people without any compromise on quality. Through bringing together advanced technologies, precision medicine and compassionate care, we are not merely treating cancer — we are redefining what the patient experience is. As we carry on with this journey, our focus stays on empowering patients to achieve the best possible outcomes, while we drive innovation and transform cancer care throughout India. Thank you for your continued trust and support on this journey. With that, I will hand things over to Ms. Ruby, our CFO, for the financial highlights.
Ruby Ritolia
executiveThank you, Raj, and good morning, everyone. As Raj pointed out, I'm happy to report that our results for this quarter once again show solid business momentum and continued growth. We posted a strong 19% increase in revenue year-on-year, taking our top line to INR 559 crores for the quarter. On top of that, for the 9 months that ended December 31, 2024, we achieved a robust 16% growth, with total revenue of INR 1,638 crores. One of the standout features of our results was the outstanding growth at our core HCG centers, leaving out Milann, where revenue rose by a notable 21% and EBITDA grew 16% year-on-year, which works out to a 20% EBITDA margin. Turning to our oncology centers — that is, excluding Milann, multi-specialty and the recently acquired MG, Vizag — we saw revenue climb 18% and EBITDA rise 14% year-on-year, at a 21% EBITDA margin. These figures confirm once again that we can consistently outpace industry growth, thanks to our dedication to clinical excellence, operational efficiencies and an unwavering focus on patient care. We are confident that we can deliver stronger growth in quarter 4 of FY '25, with significant increases expected in both revenue and EBITDA. A major factor behind our continued success has been strong performance across multiple modalities, backed by rising patient volumes and better capacity utilization.
Ruby Ritolia
executiveWhat we've put into medical infrastructure, specialized treatments, strong clinical talent, and patient care keeps producing positive results. On top of that, in the quarter we consolidated revenue from Mahatma Gandhi Memorial Hospital, and it added INR 25 crores at an impressive 24% margin. That integration makes our portfolio stronger still and fits our long-term growth strategy, letting us scale operations while keeping strong financial discipline. I'd also like to point out that the restructuring of our diagnostic business under the brand name Triesta has been completed successfully. This will help foster large scale and wider reach to non-captive businesses as well. Our key operating metrics showed significant improvement this quarter. OPD footfall, a crucial indicator of our conversion funnel, rose by 9%, highlighting rising patient trust and engagement. In medical oncology, we recorded 19% growth in chemotherapy sessions, underscoring the continued expansion of our patient base. Capacity utilization of our LINAC machine reached 60%. And despite adding 7 new LINAC machines in last 12 months, our ability to maintain this utilization rate showcases the efficiency and robustness of our operations. In addition, our patient bed occupancy rate improved from 52% in quarter 3 of FY '24 to 55% in quarter 3 of FY '25, reinforcing our commitment to optimize facility utilization and enhancing patient access to world-class oncology care.
Ruby Ritolia
executiveNow moving on to the heart of what we do. This quarter, both our mature facilities and the newer ones turned in really solid results. At our established centers, growth has been consistent — revenue came in 20% higher than the same period a year earlier, and EBITDA rose by 14%. Meanwhile, the emerging centers posted outstanding numbers, with revenue up 25% and EBITDA climbing an impressive 65% during the quarter. In particular, our Kolkata center stood out, delivering remarkable revenue growth of 40% and EBITDA growth of 42x, while South Mumbai recorded a robust 28% increase and Borivali came in at 11% growth. These locations are central to how we expand, since they sit in Tier 1 cities with sizable catchment areas and act as important hubs for patients from abroad. Their ongoing growth confirms that we can meet rising demand while bringing advanced oncology care to more patients. On ARPOB, the total rose 3.5% to INR 44,284. At established centers, ARPOB increased 2.8% to INR 42,798, while emerging centers saw a strong 12.3% rise to INR 66,000. Capex for the year is projected at INR 275 crores, and INR 172 crores of that has already been spent.
Ruby Ritolia
executiveFor the 9 months that concluded on 31st December 2024, our effective tax rate stands at 3%, which came about because of deferred tax recognition at our subsidiary amounting to INR 12 crores. That covers the performance summary we wanted to share. At this point, I'd like to open the floor to participants for any questions regarding the performance.
Operator
operator<<operator_script>> Our first question comes from Aditya Khemka, who is on the line from InCred PMS.
Aditya Khemka
analystAnd congratulations to the team on the deal as well. So a few questions about the contour following the deal. So CVC, as we understand it, will keep holding a 9% stake, and Dr. Ajai obviously retains a stake of 10.8-odd percent in the company. So could you help us understand whether KKR makes the open offer of 26% after buying 51% in the company? And in terms of the total holding among CVC, KKR and Dr. Ajai, that will probably potentially rise to 95%, 96%, right, because it's 10% plus, 9% plus a potential 77% with KKR, including the open offer price. So how should we read that? I understand that Dr. Ajai and CVC are now classified as public shareholders. Does that also mean that, in terms of operations of the business?
B. Kumar
executiveNo, no — I just want to set you straight on that. The CVC is going to be treated as public shareholders. I'll remain a promoter. So here's how it works: in our calculation, at the most, KKR can go up — depending on what the open offer percentage turns out to be, they could reach as high as — there's a clause allowing KKR to go up to 77%, but only if that happens through the open offer. Otherwise — sorry, up to 60% — 67%, because I'll also be classified as a co-promoter along with them. So we'll be looking at it under that scenario. As things stand, to be clear, the CVC will be at just 9.9% or even lower, depending on what happens with the open offer and how they might come down. So based on that calculation, which we really can't work out right now, it all hinges on how many people participate in the open offer. So I'll leave it at that. But basically, together with KKR, we'll be holding close to — at the maximum, we can reach 77%, and then we have to decide what to do, okay?
Aditya Khemka
analystGot it, sir, that clears things up quite a bit. And sir, regarding the position you hold at the organization now, the press release says you're no longer serving in an executive capacity. So should we take that to mean you'd function more as a financial investor in the company, with only limited involvement in routine operations? Or is that not quite how it works?
B. Kumar
executiveYes. Let me make that clearer, because since I founded HCG and began working in operations as Executive Chairman, I've reached a point where my real interest has always lain in research, clinical excellence for patients, and academics. So my position will be Chairman of the Board, with a clearly defined involvement in clinical excellence, research, and academics. We will also serve as a promoter — co-promoter alongside them. And of course, as promoters, we'll be meeting and we'll have a growth strategy. As we go forward, we've talked with KKR about getting together on a monthly basis. So we'll have certain arrangements in place. But my role — certainly, even now, my operational role is quite limited. So certainly, I'll be limited in operations, or not in operations at all, sir. Going forward, I won't be involved in day-to-day operations, okay? But my interest, as I mentioned, lies in research and academics, and I'll be devoting more time to that — advancing genomics and proteomics, all of those areas, collecting data. Data matters enormously in oncology, as we all know. How are we performing when it comes to outcomes? So my focus will be on outcomes, and on publications about outcomes.
B. Kumar
executiveAnd that's what I trained in at MD Anderson, even years ago. The outcome for a cancer patient matters most. If you're aware of our outcomes and how we handle advanced and recurrent tumors, that in itself is what makes it a center of excellence. So I'll be focusing on building those centers of excellence so that oncology patients feel comfortable receiving treatment at HCG across our entire HCG network.
Operator
operatorOur next question comes from Gautam Rakesh, who is calling in from Leo Capital.
Gautam Rakesh
analystThere are a couple of things I wanted to ask about. First, how do you expect margins to trend as we look out over the coming year? That's my first one.
Ashutosh Kumar
executiveThis is Ashutosh calling in from HCG, from Corporate. So when we discuss that margin for the years ahead, I'd like to use this chance to also cover the margins — how things played out in quarter 3 and what we expect for the coming quarters and then next year. To refresh everyone's memory, our EBITDA margin stood at 18.5% in quarter 2, and it dropped to roughly 16% in Q3. The main reason, as we're all aware, is that quarter 3 brings festivities, which cause some seasonality and hold us back from operating leverage. As we head into Q4, with revenue scaling up and our modality mix normalizing, we anticipate the margin expanding beyond what we reported in quarter 2. That's our current view of it. From these levels, we ought to improve our EBITDA margin on our existing portfolio. And as we've announced, we will be operationalizing 2 new brownfield centers in Bangalore. Some losses are expected to come from those. Still, the EBITDA margin expansion in the current portfolio should largely offset that.
Ashutosh Kumar
executiveFrom where margins sit right now, we ought to see them widen in the coming financial year, by roughly 1%, 1.5%.
Analyst
analystYou're saying it could go up to 1% to 1.5%?
Ashutosh Kumar
executiveCorrect — that includes the losses we'd incur from the new centers.
Analyst
analystGot it, got it. And the final question I had was: what rate are we anticipating for same-store asset growth? And at what rate do you expect those to be sustained?
Meghraj Gore
executiveApologies — would you mind repeating your question? I couldn't quite hear it; it came through a bit unclear.
Analyst
analystAll right, all right. At what rate are the same-store assets we already have growing? And at what rate do we expect that growth to be sustained?
Ashutosh Kumar
executiveThe centers we already have in place have been expanding at rates above 12% and 13%. And as everyone is aware, growth for that market has come in at roughly 11%. We've told the Street that we'd expand more quickly than that — our established centers ought to also outpace the market's growth rate. We've put substantial investment into our current assets in order to accelerate that growth. And at this point, capacity isn't a constraint for us at any locations except 1 or 2. We're also — we're investing to make sure capacity doesn't become a bottleneck. So I believe we should keep growing above 13% and 14% at our established centers for overall growth, and as we all know that...
Analyst
analystCould you say that again? It came through unclear. Keep growing at what rate?
Ashutosh Kumar
executiveFor the future, we're looking at 13% to 14%.
Operator
operator<<operator_script>> Our following question comes from Sagar Tanna with Alchemie Ventures.
Sagar Tanna
analystCould you talk about how the Bombay centers are doing — both Borivali and the South Bombay center — when it comes to EBITDA performance? What did that look like last year? And what are we expecting for the coming year? You brought up 100, 150 bps of EBITDA expansion. Would the turnaround at the Bombay center also contribute to that? If you could elaborate, that would help.
Ashutosh Kumar
executiveYou're absolutely right that our emerging centers will make a meaningful contribution. As a reminder, 3 of our centers are classified as emerging centers — 1 in Kolkata and 2 in Mumbai. In Kolkata, we announced that we had already broken even in quarter 1. We continue to — I mean, we take it positively from there. As for our Mumbai centers, Borivali is doing good, and Borivali has been performing in the past. What we have been trying to focus on is primarily South Mumbai. As far as South Mumbai profitability is concerned, we did not see reduction of profitability of the South Mumbai center in quarter 3, primarily because we had a subdued international business for the reasons Raj explained in his opening speech. However, we do expect the reduction of losses in South Mumbai by at least INR 1 crore. And by quarter 1 of next financial year, we should be seeing the center breaking even and expand from there. So obviously, emerging centers, which is growing today at the rate of almost about 25%, we expect similar growth to continue and should result into reduction of losses and have an upward trajectory in terms of EBITDA margin.
Sagar Tanna
analystSir, regarding the South Bombay center, on a full-year basis for FY '25, what sort of EBITDA loss are we anticipating?
Ashutosh Kumar
executiveWhen it comes to emerging centers, my guess is it would land somewhere around — South Mumbai?
Sagar Tanna
analystYes.
Ashutosh Kumar
executiveIn South Mumbai, the figure will land somewhere around INR 10 crores to INR 11 crores, almost.
Sagar Tanna
analystThat came to roughly INR 35 crores in losses last year, if my recollection serves. Do I have that right?
Ashutosh Kumar
executiveNo, it didn't reach INR 35 crores. It would be somewhat above what we're seeing in the current year.
Sagar Tanna
analystUnderstood. And you're expecting that to reach break-even in the next financial year?
B. Kumar
executiveIt's declining, and — yes.
Operator
operatorDoes that address what you were asking, sir?
Sagar Tanna
analystCorrect.
Operator
operatorOur next question comes from Yash Sinha, who is on the line from MIPL.
Yash Sinha
analystCongrats on the deal and on the strong results this quarter. There are 2 things I'd broadly like to get a handle on. First, given all the guidance you've provided across the last 3 or 4 quarters, is there anything in particular that shifts because of the new acquisition? Second, I was hoping for some color on your CapEx guidance over the next 2 to 3 years. What does it look like year by year? And which specific areas are you concentrating on?
B. Kumar
executiveCould you clarify what you mean regarding new acquisition?
Yash Sinha
analystNow that the KKR acquisition is coming in, do you expect any meaningful shift in your business plans and in what you've been guiding over roughly the last 3 or 4 quarters?
B. Kumar
executiveYes. At this point, we haven't held any detailed discussions with KKR. The only thing I can say is that, since they're coming in as a new investor now, we will certainly be looking at a long-term plan, which we'll lay out as we move forward and develop the partnership with them. And so at that point, we can certainly elaborate when we have certainty. But as of now, our certainly model is to stay on course to grow the existing centers and also to see that whatever recent acquisition we have done will meet our expectation and continue to focus on operational excellence, clinical excellence and improve the margin as what Raj, Ruby and Ashutosh have said, okay?
Yash Sinha
analystUnderstood.
B. Kumar
executiveDid you have another question?
Yash Sinha
analystThe second thing I wanted to ask about is just some direction on what your yearly capital expenditure will look like over the coming 2 to 3 years, and which particular areas that spending is going to be concentrated on?
Ashutosh Kumar
executiveEarlier we had given the Street guidance on the CapEx side, and that remains unchanged. Mainly, lumpy CapEx is expected to occur in the current year, FY '25, and the next financial year, FY '26, at roughly INR 275 crores to INR 280 crores per annum. Out of that, approximately INR 100 crores per annum would be our maintenance CapEx. As of today, whatever growth plans we have set out — including the new centers that would be operationalized in FY '26 and the expansion that has happened in FY '25 — we should be more or less finished with our growth CapEx plan that exists today by FY '26. After that, we should normalize to about INR 100 crores of maintenance CapEx thereafter, with some inflation in that.
Operator
operator<<operator_script>> Our following question comes from Ravi Shah at VRS Capital.
Ravi Shah
analystSir, I have two questions. First, what's our outlook for the international patient business at the South Mumbai center? And are we seeing any recovery there?
Meghraj Gore
executiveYeah. So this is Raj. What we've observed on the international side is that we began the year quite strongly. Q1 ranked among our best. From Q2 onward, with the unrest in Bangladesh, we felt an impact. Q3 was the weakest, since the Indian government cut back on medical visas granted to Bangladeshi patients traveling to India. So Q3 was our weakest. We anticipate Q4 returning to the Q2 level. And after that, looking ahead, in the year to come, we believe things ought to normalize.
B. Kumar
executiveAnd Raj, would it be accurate to say — I just want to add to that — that most of the hospital industry is dealing with this same issue? Is that a fair statement, Raj?
Meghraj Gore
executiveRight. Bangladesh, as you know, accounts for most of the medical tourism business coming into Indian hospitals and contributes more than anyone else. This is something seen industry-wide across the country. And our hope is that as political ties return to normal, the usual flow of patients from Bangladesh into India will pick back up, and we'll get back on track.
Analyst
analystGot it, sir. Sir, my second question is also about the international side. So how much do international patients contribute overall to revenue at the company level? And what would the outlook be going forward for that?
Meghraj Gore
executiveYeah. So that's roughly 3.5% to 4%, and we anticipate it staying at that level as we move ahead. As you're aware, we've got a really aggressive agenda for growth here at home. So we expect that figure to keep coming in at 3.5%, 4% in the future.
Ashutosh Kumar
executiveTo build on Raj's comments, things may be subdued this year for those reasons. Even so, we expect a return to 3.5%.
Operator
operator<<operator_script>> We'll now take our next question from Devang Patel, who is calling in from Sameeksha Capital.
Devang Patel
analystSir, I asked about margins at established centers, where according to the PPT we've seen 20% revenue growth and 14% EBITDA growth, which implies EBITDA margins are lower on a Y-o-Y basis. That's even though, as you mentioned earlier, MG hospitals are being added with higher margins of 24%, 25%. So what's the reason margins are lower Y-o-Y?
Ashutosh Kumar
executiveAs we just walked through, we covered that in terms of dilution across overall margins. But the same holds true for our established centers too. Sequentially, we're seeing revenue decline in quarter 3, which puts us at a disadvantage since we don't get to benefit from operating leverage. That held back operating leverage in quarter 3, which brought EBITDA lower, including MGM. This is something happening across the industry, and MGM is part of that. That said, as we've mentioned, when we get into quarter 4, things have been normalizing, with our revenues also coming in higher than quarter 2, the way we see it. We ought to see margin expansion take place. So this was only a quarter 3 phenomenon, and we should be past it in quarter 4.
Devang Patel
analystSir, on the quarter-over-quarter margin — your explanation was clear, and we get the seasonality piece. What I was really asking about is the year-over-year comparison, since seasonality would have hit last year as well. Looking at it year over year, for established centers the EBITDA growth comes in below the revenue growth.
Ashutosh Kumar
executiveThat's correct. And on top of that, we also noted what else we've observed — although revenue declined quarter over quarter, pharmacy revenue came in comparatively stronger than our other modality business, which is typically a high gross margin business. As this normalizes in the coming quarter, quarter 4, we should see our margin recover. So the lower gross margin was mainly because of the higher pharmacy business, along with lower operating leverage driven by the revenue reduction.
Devang Patel
analystRight, sir — and at the PBT level, after interest and depreciation, EG Hospital would carry some drag. Could you share that figure?
Ashutosh Kumar
executiveI apologize, but up to now we haven’t shared any information about asset levels. So at this point in time, we’re able to hold off on that.
Devang Patel
analystAlright. Sir, and last of all, regarding the Milann business, that top line is still shrinking. Could you just lay out what our plan is to turn that business around, and following the stake sale, would you be taking a fresh look at this business?
B. Kumar
executiveAs everyone is aware, historically we've examined Milann and considered what its future holds regarding a divestment. That said, as we've outlined, the promoter — Milann's original founder — left the business, and her non-compete period has now ended. Given that situation, she has opened a handful of her own clinics quite near ours. As a result, especially at Kumara Park in J.P. Nagar, revenue has declined. That said, I'm glad to report that the situation is improving. Looking ahead to the coming quarters — in particular last month and the next few quarters — we ought to return to prior levels and keep delivering gains. At the same time, a decision remains about when exactly we should divest it. We'll be evaluating that too as we go forward. Another area where Milann has lately shown strength is andrology. Going forward, we're very pleased to say that Milann has a robust andrology department, and it will genuinely drive our growth. After all, historically we had always focused on fertility concerns affecting women.
B. Kumar
executiveYet if you examine the figures, honestly 50% — or 40% to 50% — of fertility problems stem from male-related factors, and that has been entirely overlooked in fertility care. So we've embraced that issue very seriously. We're bringing male and female fertility together. Our centers will deliver that type of center of excellence we're working to build, and we'll also examine where things may have gone wrong early on, how we can combine both sides and try to enhance the outcomes. We're concentrating — just as we've done in oncology — we're likewise concentrating on the outcomes. So this situation represents a turnaround. We hold a strong belief that with the kind of advanced clinics we have, we've got a solid opportunity to grow back. As you're aware, in India, we believe infertility is turning into a major problem. Fertility must be tackled for a range of reasons, which I've covered previously; unfortunately, Milann went through a tough cycle. And at this point I believe we're past that cycle, and we'll see meaningful improvement going forward. In addition, we'll look at the chance to divest at the right moment.
Operator
operator<<operator_script>> Our following question comes from Sakshi Pratap of Pratap Securities.
Sakshi Pratap
analystI’ve got 2 questions I’d like to ask. First, what’s our growth strategy going forward? Would it be led by acquisitions? Could you shed some light on that?
B. Kumar
executiveMoving forward — ours — yes, am I coming through okay?
Analyst
analystCorrect.
B. Kumar
executiveAs I mentioned, moving forward our approach will definitely involve ensuring that current centers achieve their maximum growth potential. And we do see the full potential in centers of excellence. We have new centers launching in Bangalore, along with our hub-and-spoke model infusion clinics. That's where we expect substantial growth to occur. At the same time, we will definitely explore merger acquisitions, just as we did in Vizag, where we'll seek out strategic opportunities that allow us to build dedicated oncology and grow. As we know, there aren't that many dedicated oncology centers available in merger acquisition. So we'll consider that, along with a mix of greenfield and brownfield — very limited — but we also look at growth from existing centers. All of this will be discussed appropriately with our new partner as we move forward. On that note, I'd like to check whether Raj Gore would like to add anything — please go ahead.
Meghraj Gore
executiveNo, Dr. Ajai, you've addressed that. We've consistently told the market that through brownfield capacity expansion at our existing hospitals, we have sufficient headroom, and given our leading share in every market where we operate, there's ample potential to generate organic growth within those existing hospitals. That will remain the main driver going forward — our organic plus brownfield growth. And then, at the right moment with the new partners, we'll determine how to supplement that through inorganic growth going forward.
Analyst
analystGot it, understood. And for the open offer, what would the timeline be?
B. Kumar
executiveI believe it depends on the specifics, though I can't say for certain. Is there anyone here who can answer that?
Meghraj Gore
executiveI'll do my best to respond. Look, I think the requirement to tender this offer comes from the particular process and schedules that the regulators have set out. That offer is something KKR is required to carry out. And once they reveal additional details in line with the process as established, we'll have those answers in due course.
Operator
operatorDhruv Shah from Dalal & Broacha has the next question.
Dhruv Shah
analystSir, just a single question regarding your debt level. So right now it stands at roughly INR 1,500-odd crores, and in the past we have observed that it has been rising consistently. So at what kind of debt levels would you feel comfortable? And when do we see debt repayment beginning from?
Ruby Ritolia
executiveRight now, with the debt levels we have, we feel very comfortable with every banking covenant in place. What you brought up does include capital leases. But if capital leases were taken out, our net debt — especially the banking portion — comes to roughly INR 650-odd crores. At that level we're quite comfortable, and given the growth and the CapEx investment we've laid out for this year and for next year, we'll stay comfortable within our debt positions.
Dhruv Shah
analystSure. Just one thing on the CapEx you've got underway. So we're still on the current timeline, correct? There's no delay when it comes to opening the CapEx that's in progress, right?
Ashutosh Kumar
executiveWe're pretty much on schedule when it comes to getting our centers operational. Yes.
Operator
operatorLadies and gentlemen, because of time constraints, we’ll treat that as the final question. At this point, I’d like to turn the conference back to management for closing remarks.
Meghraj Gore
executiveThanks again for being so engaged on this call. As I said, we're glad that we'll be able to boost shareholder value the right way by concentrating on the — which is what's right for cancer patients. We're very enthusiastic about what this organization can do, and at the moment we're focused on finishing the year on a very strong note and planning for, again, solid year-on-year growth in both top line and bottom line next year. We'll keep you posted. Thank you for backing the organization. Thank you.
Operator
operatorThanks. That brings us to the end of this conference on behalf of HealthCare Global Enterprises Limited. We appreciate everyone for joining, and you can go ahead and disconnect your lines now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete HealthCare Global Enterprises Limited transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to HealthCare Global Enterprises Limited earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in HealthCare Global Enterprises Limited or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.